Terrorlim
2021-07-21
Yeah
EXCLUSIVE: Celularity's CEO On 'One-Size-Fits-All' Product, Palantir Connection
免责声明：上述内容仅代表发帖人个人观点，不构成本平台的任何投资建议。
分享至
微信
复制链接
精彩评论
我们需要你的真知灼见来填补这片空白
打开APP，发表看法
APP内打开
发表看法
2
{"i18n":{"language":"zh_CN"},"detailType":1,"isChannel":false,"data":{"magic":2,"id":176818927,"tweetId":"176818927","gmtCreate":1626875863169,"gmtModify":1633770204249,"author":{"id":3585692776043544,"idStr":"3585692776043544","authorId":3585692776043544,"authorIdStr":"3585692776043544","name":"Terrorlim","avatar":"https://static.tigerbbs.com/fe3c53ba1d6834839da488e14e9c99a8","vip":1,"userType":1,"introduction":"","boolIsFan":false,"boolIsHead":false,"crmLevel":2,"crmLevelSwitch":0,"individualDisplayBadges":[],"fanSize":0,"starInvestorFlag":false},"themes":[],"images":[],"coverImages":[],"extraTitle":"","html":"<html><head></head><body><p>Yeah</p></body></html>","htmlText":"<html><head></head><body><p>Yeah</p></body></html>","text":"Yeah","highlighted":1,"essential":1,"paper":1,"likeSize":2,"commentSize":0,"repostSize":0,"favoriteSize":0,"link":"https://laohu8.com/post/176818927","repostId":1121414767,"repostType":4,"repost":{"id":"1121414767","weMediaInfo":{"introduction":"Stock Market Quotes, Business News, Financial News, Trading Ideas, and Stock Research by Professionals","home_visible":0,"media_name":"Benzinga","id":"1052270027","head_image":"https://static.tigerbbs.com/d08bf7808052c0ca9deb4e944cae32aa"},"pubTimestamp":1626871035,"share":"https://www.laohu8.com/m/news/1121414767?lang=&edition=full","pubTime":"2021-07-21 20:37","market":"us","language":"en","title":"EXCLUSIVE: Celularity's CEO On 'One-Size-Fits-All' Product, Palantir Connection","url":"https://stock-news.laohu8.com/highlight/detail?id=1121414767","media":"Benzinga","summary":"FormerPepsiCo Inc PEPpresident andApple IncAAPLCEOJohn Sculleyraved about Celularity IncCELUMonday o","content":"<p>Former<b>PepsiCo Inc</b> PEPpresident and<b>Apple Inc</b>AAPLCEO<b>John Sculley</b>raved about <b>Celularity Inc</b>CELUMonday on Benzinga's YouTube show \"Power Hour.\"</p>\n<p>Celularity founder and CEO<b>Robert Harini</b>appeared on \"Power Hour\" for an exclusive interview Tuesday.</p>\n<p>Celularity went public via special purpose acquisition company <a href=\"https://laohu8.com/S/GXGX\">GX Acquisition</a> Corp. on July 16.</p>\n<p>Celularity focuses on delivering cellular medicines derived from the postpartum human placenta, Harini told Benzinga.</p>\n<p>Sculley is a founding director and vice chairman of the board at Cellularity.</p>\n<p>Harini said he's fortunate to work on the noble pursuit of transforming living cells into medicine with Sculley. Harini went on to talk more about Sculley, an award he received from<b>Pope Francis</b>and more.</p>\n<p><b>Key Highlights:</b></p>\n<ul>\n <li>The human placenta is \"nature's stem cell factory.\" Celularity uses the placenta to produce a product that is \"<a href=\"https://laohu8.com/S/AONE.U\">one</a>-size-fits-all.\"</li>\n <li>Celularity uses<b>Palantir Technologies Inc</b>PLTR 0.05%to enhance the quality of its products. Palantir sought out the partnership because of its deep interest in biological science and the health care industry.</li>\n <li>One great future opportunity will be to find ways to mitigate the degenerative changes that occur with aging. Cellular biology is \"here to stay.\"</li>\n <li>Harini developed his passion after being intrigued by the possibility for stem cells to be used as a tool for restoring function in a damaged brain.</li>\n <li>He believes Celularity's future products will have the quality and economics to help lead the industry.</li>\n</ul>\n<p><b>CELU Price Action:</b>Celularity shares gained 4.05% Tuesday, closing at $21.85.</p>","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>EXCLUSIVE: Celularity's CEO On 'One-Size-Fits-All' Product, Palantir Connection</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nEXCLUSIVE: Celularity's CEO On 'One-Size-Fits-All' Product, Palantir Connection\n</h2>\n\n<h4 class=\"meta\">\n\n\n<div class=\"head\" \">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://static.tigerbbs.com/d08bf7808052c0ca9deb4e944cae32aa);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Benzinga </p>\n<p class=\"h-time\">2021-07-21 20:37</p>\n</div>\n\n</div>\n\n\n</h4>\n\n</header>\n<article>\n<p>Former<b>PepsiCo Inc</b> PEPpresident and<b>Apple Inc</b>AAPLCEO<b>John Sculley</b>raved about <b>Celularity Inc</b>CELUMonday on Benzinga's YouTube show \"Power Hour.\"</p>\n<p>Celularity founder and CEO<b>Robert Harini</b>appeared on \"Power Hour\" for an exclusive interview Tuesday.</p>\n<p>Celularity went public via special purpose acquisition company <a href=\"https://laohu8.com/S/GXGX\">GX Acquisition</a> Corp. on July 16.</p>\n<p>Celularity focuses on delivering cellular medicines derived from the postpartum human placenta, Harini told Benzinga.</p>\n<p>Sculley is a founding director and vice chairman of the board at Cellularity.</p>\n<p>Harini said he's fortunate to work on the noble pursuit of transforming living cells into medicine with Sculley. Harini went on to talk more about Sculley, an award he received from<b>Pope Francis</b>and more.</p>\n<p><b>Key Highlights:</b></p>\n<ul>\n <li>The human placenta is \"nature's stem cell factory.\" Celularity uses the placenta to produce a product that is \"<a href=\"https://laohu8.com/S/AONE.U\">one</a>-size-fits-all.\"</li>\n <li>Celularity uses<b>Palantir Technologies Inc</b>PLTR 0.05%to enhance the quality of its products. Palantir sought out the partnership because of its deep interest in biological science and the health care industry.</li>\n <li>One great future opportunity will be to find ways to mitigate the degenerative changes that occur with aging. Cellular biology is \"here to stay.\"</li>\n <li>Harini developed his passion after being intrigued by the possibility for stem cells to be used as a tool for restoring function in a damaged brain.</li>\n <li>He believes Celularity's future products will have the quality and economics to help lead the industry.</li>\n</ul>\n<p><b>CELU Price Action:</b>Celularity shares gained 4.05% Tuesday, closing at $21.85.</p>\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"CELU":"Celularity Inc."},"is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"1121414767","content_text":"FormerPepsiCo Inc PEPpresident andApple IncAAPLCEOJohn Sculleyraved about Celularity IncCELUMonday on Benzinga's YouTube show \"Power Hour.\"\nCelularity founder and CEORobert Hariniappeared on \"Power Hour\" for an exclusive interview Tuesday.\nCelularity went public via special purpose acquisition company GX Acquisition Corp. on July 16.\nCelularity focuses on delivering cellular medicines derived from the postpartum human placenta, Harini told Benzinga.\nSculley is a founding director and vice chairman of the board at Cellularity.\nHarini said he's fortunate to work on the noble pursuit of transforming living cells into medicine with Sculley. Harini went on to talk more about Sculley, an award he received fromPope Francisand more.\nKey Highlights:\n\nThe human placenta is \"nature's stem cell factory.\" Celularity uses the placenta to produce a product that is \"one-size-fits-all.\"\nCelularity usesPalantir Technologies IncPLTR 0.05%to enhance the quality of its products. Palantir sought out the partnership because of its deep interest in biological science and the health care industry.\nOne great future opportunity will be to find ways to mitigate the degenerative changes that occur with aging. Cellular biology is \"here to stay.\"\nHarini developed his passion after being intrigued by the possibility for stem cells to be used as a tool for restoring function in a damaged brain.\nHe believes Celularity's future products will have the quality and economics to help lead the industry.\n\nCELU Price Action:Celularity shares gained 4.05% Tuesday, closing at $21.85.","news_type":1},"isVote":1,"tweetType":1,"viewCount":196,"commentLimit":10,"likeStatus":false,"favoriteStatus":false,"reportStatus":false,"symbols":[],"verified":2,"subType":0,"readableState":1,"langContent":"EN","currentLanguage":"EN","warmUpFlag":false,"orderFlag":false,"shareable":true,"causeOfNotShareable":"","featuresForAnalytics":[],"commentAndTweetFlag":false,"andRepostAutoSelectedFlag":false,"upFlag":false,"length":4,"xxTargetLangEnum":"ORIG"},"commentList":[],"isCommentEnd":true,"isTiger":false,"isWeiXinMini":false,"url":"/m/post/176818927"}
精彩评论